Agents and Actions

, Volume 11, Issue 6–7, pp 673–678 | Cite as

Pharmacologic characterization of immune complex induced bronchoconstriction in guinea pigs

  • Z. E. Mielens
  • E. W. Ferguson
  • R. A. Ferrari
Histamine and Kinins


Intravenous injections of soluble immune complexes to anesthetized guinea pigs resulted in bronchoconstriction that was inhibited by FPL 55712, indomethacin, oxarbazole, soybean trypsin inhibitor, and cobra venom factor. Immune complex induced bronchoconstriction was not inhibited by atropine, imidazole, mepyramine, ketotifen, methysergide, and the anti-anaphylactic compound DPP (Diethyl |2-(4-pyridyl)-4-pyrimidinyl|aminoethylene malonate).

Immune complex induced bronchoconstriction in guinea pigs appears to involve activation of complement and formation of anaphylatoxins. In addition, products of cyclo-oxygenase metabolism of arachidonic acid and kinins may be involved.


Arachidonic Acid Indomethacin Immune Complex Malonate Aminoethylene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    J. Lefort andB.B. Vargaftig,Mechanisms of collagen induced bronchoconstriction and thrombocytopenia in the guinea pig, Br. J. Pharmac.62, 422 P (1978).Google Scholar
  2. [2]
    Z.E. Mielens,The effects of anti-asthmatic drugs against immune complex induced bronchoconstriction in anesthetized dogs, Pharmacology18, 311–318 (1979).PubMedGoogle Scholar
  3. [3]
    Z.E. Mielens,Evaluation of the anti-asthmatic potential of oxarbazole in guinea pigs. Pharmacology17, 323–329 (1978).PubMedGoogle Scholar
  4. [4]
    H.R. Morris, P.J. Piper, G.W. Taylor andJ.R. Tippins,Comparative studies on immunologically and non-immunologically produced slow reacting substances from man, guinea pig and rat. Br. J. Pharmac.67, 179–189 (1979).Google Scholar
  5. [5]
    C.A. Williams andM. Chase,Methods in immunology and immunochemistry, vol. 1, pp. 201. Academic Press, New York 1967.Google Scholar
  6. [6]
    D.J. Finney, Parallel line assay. InStatistical methods in biological assay, p. 99. McMillan, New York 1978.Google Scholar
  7. [7]
    C. Takeguchi, E. Kohno andC.H. Sih,Mechanism of prostaglandin biosynthesis. I. Characterization and assay of bovine prostaglandin synthetase. Biochemistry10, 2372–2376 (1971).CrossRefPubMedGoogle Scholar
  8. [8]
    L. Craps, Le ketotifene: Données expérimentales et cliniques. Schweiz. Med. Wochenschr.110, 187–191 (1980).PubMedGoogle Scholar
  9. [9]
    H. Tomioka, S. Yoshida, M. Tanaka andA. Kumasai,Inhibition of chemical mediator release from human leucocytes by a new anti-asthma drug. KC-20-511 (Ketotifen), Monogr. Allergy14, 313–317 (1979).Google Scholar
  10. [10]
    I. Broder andN.S. Taichman,Mechanism of histamine release from perfused guinea-pig lung by soluble immune complexes, Immunology21, 193 (1971).PubMedGoogle Scholar
  11. [11]
    H.O.J. Collier, G.W.L. James andP.J. Piper,Antagonism by fenamates and like-acting drugs of bronchoconstriction induced by bradykinin or antigen in guinea pig, Br. J. Pharmac.34, 76–87 (1968).Google Scholar
  12. [12]
    N. Chand, FPL 55712 —An antagonist of slow reacting substance of anaphylaxis (SRS-A): A review, Agents and Actions9, 133–140 (1979).PubMedGoogle Scholar
  13. [13]
    A.M. Reynard,The regulation of complement activity by pharmacologic agents, J. Immunopharmac.2, 1–47 (1980).CrossRefGoogle Scholar
  14. [14]
    D.S. Fletcher andTsau-Yen Lin,Inhibition of immune complex-mediated activation of complement, Inflammation4, 113–123 (1980).CrossRefPubMedGoogle Scholar
  15. [15]
    A.N. Theofilopoulos andF.J. Dixon,The biology and detection of immune complexes, Adv. Imm.28, 89–221 (1979).Google Scholar
  16. [16]
    T.E. Hugli andH.J. Mueller-Eberhard,Anaphylatoxins C3a and C5a, Adv. Imm.26, 1–58 (1978).Google Scholar
  17. [17]
    J.F. Regal, A.Y. Eastman, R.J. Pickering,C5a induced tracheal contraction: A histamine independent mechanism, J. Immunol.129, 2876–2878 (1980).Google Scholar
  18. [18]
    H.Z. Movat andN.L. DiLorenzo,Activation of the plasma kinin system by antigen-antibody aggregates: I. Generation of permeability factor in guinea pig serum, Lab. Invest.19, 187–200 (1968).Google Scholar
  19. [19]
    V. Eisen andH.G. Smith,Plasma kinin formation by complexes of aggregated globulin and serum proteins, Br. J. Exp. Path.51, 328–331 (1970).Google Scholar
  20. [20]
    C.G. Cochrane, K.D. Wuepper, B.S. Aiken, S.D. Revak andH.L. Spiegelberg,The interaction of Hageman factor and immune complexes. Jr. Clin. Invest.51, 2736–2745 (1972).Google Scholar
  21. [21]
    H.H. Newball, H.L. Meier, A.P. Kaplan, S.D. Devak, C.G. Cochrane andL.M. Lichtenstein,Anaphylactic activation of the Hageman factor (HF) dependent pathways. In4th International Congress of Immunology, (EdsJ.L. Trend ‘Homme andV.A.L. Hawken) Davis 1980.Google Scholar
  22. [22]
    J.J. Pisano,Chemistry and biology of the kallikrein kinin system. InProteases and Biological Control, pp. 199–222. (EdsReich, Rifkin, Shaw) Cold Spring Harbor Laboratories 1975.Google Scholar
  23. [23]
    R.J. Flower,Drugs which inhibit prostaglandin biosynthesis, Pharmac. Reviews26, 33–67 (1974).Google Scholar
  24. [24]
    M.A. Palmer, P.J. Piper andJ.R. Vane,Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea pig lungs, Br. J. Pharmac.49, 226–242 (1973).Google Scholar
  25. [25]
    B.B. Vargaftig andN. Dao Hai,Release of vaso-active substances from guinea-pig lungs by slow reacting substance and arachidonic acid, Pharmacology6, 99 (1971).PubMedGoogle Scholar
  26. [26]
    H.C. Sackeyfio,Anaphylatoxin-induced release of a substance with prostaglandin-like activity in isolated perfused guinea pig lungs, Br. J. Pharmac.46, 544 P (1972).Google Scholar
  27. [27]
    H.C. Sackeyfio,A comparison of the histopathological effects of anaphylatoxin (AT) and prostaglandins E 2 and F (Pg F )in guinea pig lungs, Br. J. Pharmac.55, 240 P (1975).Google Scholar
  28. [28]
    N.P. Stimler, W.E. Brocklehurst, C.M. Bloor, T.E. Hugli,complement anaphylatoxin C5a stimulates release of SRS-A-like activity from guinea pig lung fragments, J. Pharmac.32, 804 (1980).Google Scholar
  29. [29]
    J. F. Regal andR.J. Pickering,C5a-Induced tracheal contraction: Effect of an SRS-A antagonist and inhibitors of arachidonate metabolism, J. Immunol.126, 313–316 (1981).PubMedGoogle Scholar
  30. [30]
    D.M. Engineer, H.R. Morris, P.J. Piper, andP. Sirois,The release of prostaglandins and thromboxanes from guinea pig lung by slow reacting substance of anaphylaxis, and its inhibition, Br. J. Pharmac.64, 211–218 (1978).Google Scholar
  31. [31]
    R.A. Coleman, I. Kennedy andRL.G. Sheldrick,A simple method for generating thromboxane A 2, Br. J. Pharmac.69, 341P-342P (1980).Google Scholar
  32. [32]
    S. Moncada, S. Bunting, K. Mullane, P. Thorogood andJ.R. Vane,Imidazole: A selective inhibitor of thromboxane synthetase, Prostaglandins,13, 611/618 (1977).CrossRefGoogle Scholar
  33. [33]
    F. Berti, G.G. Folco, A. Giachetti, S. Malandrino andC. Omini,Atropine inhibits thromboxane A 2 generation in isolated lungs of the guinea pig, Br. J. Pharmac.53, 467–472, 1980.Google Scholar

Copyright information

© Birkhäuser Verlag 1981

Authors and Affiliations

  • Z. E. Mielens
    • 1
  • E. W. Ferguson
    • 1
  • R. A. Ferrari
    • 1
  1. 1.Department of PharmacologySterling-Winthrop Research Institute, Columbia TurnpikeRensselaerUSA

Personalised recommendations